• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Approval of a tuberculosis drug based on a paradoxical surrogate measure.

作者信息

Avorn Jerry

机构信息

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA.

出版信息

JAMA. 2013 Apr 3;309(13):1349-50. doi: 10.1001/jama.2013.623.

DOI:10.1001/jama.2013.623
PMID:23430122
Abstract
摘要

相似文献

1
Approval of a tuberculosis drug based on a paradoxical surrogate measure.基于矛盾替代指标批准一种结核病药物。
JAMA. 2013 Apr 3;309(13):1349-50. doi: 10.1001/jama.2013.623.
2
MDR-TB has new drug foe after fast-track approval.耐多药结核病在快速审批后有了新的治疗药物。
JAMA. 2013 Feb 6;309(5):430. doi: 10.1001/jama.2013.94.
3
Bedaquiline (Sirturo) for multidrug-resistant tuberculosis.贝达喹啉（斯耐瑞）用于耐多药结核病。
Med Lett Drugs Ther. 2013 Aug 19;55(1423):66-8.
4
Infectious disease. Approval of novel TB drug celebrated--with restraint.传染病。新型结核病药物获批，庆祝但有所克制。
Science. 2013 Jan 11;339(6116):130. doi: 10.1126/science.339.6116.130.
5
Race heats up for first-to-market drugs for resistant tuberculosis.耐药结核病首批上市药物的竞争日益激烈。
Nat Med. 2012 Aug;18(8):1157. doi: 10.1038/nm0812-1157.
6
Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.贝达喹啉：一种用于耐多药结核病的新型抗结核药物。
J Postgrad Med. 2014 Jul-Sep;60(3):300-2. doi: 10.4103/0022-3859.138772.
7
Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis.耐多药结核病的早期生物标志物和监管创新。
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S160-3. doi: 10.1093/cid/civ612.
8
Public-private partnership tackles TB challenges in parallel.公私伙伴关系并行应对结核病挑战。
Nat Rev Drug Discov. 2009 Aug;8(8):599-600. doi: 10.1038/nrd2955.
9
Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.贝达喹啉：一种用于治疗耐多药结核病的新型抗结核药物。
Pharmacotherapy. 2014 Nov;34(11):1187-97. doi: 10.1002/phar.1482. Epub 2014 Sep 9.
10
FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.美国食品药品监督管理局批准贝达喹啉——耐多药结核病的获益-风险平衡
N Engl J Med. 2014 Aug 21;371(8):689-91. doi: 10.1056/NEJMp1314385.

引用本文的文献

1
"Weighting" the Evidence: How Much Bedaquiline Is Enough?权衡证据：多少贝达喹啉才足够？
Am J Respir Crit Care Med. 2023 Jun 1;207(11):1423-1424. doi: 10.1164/rccm.202303-0373ED.
2
Antitubercular Activity of Novel 2-(Quinoline-4-yloxy)acetamides with Improved Drug-Like Properties.具有改善类药物性质的新型2-(喹啉-4-基氧基)乙酰胺的抗结核活性
ACS Med Chem Lett. 2022 Jul 21;13(8):1337-1344. doi: 10.1021/acsmedchemlett.2c00254. eCollection 2022 Aug 11.
3
Salts and Polymorph Screens for Bedaquiline.贝达喹啉的盐类及多晶型筛选
AAPS PharmSciTech. 2021 Aug 25;22(7):228. doi: 10.1208/s12249-021-02106-7.
4
A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic.以生物标志物为中心的药物发现和开发方法：从 2019 年冠状病毒病大流行中吸取的教训。
J Pharmacol Exp Ther. 2021 Jan;376(1):12-20. doi: 10.1124/jpet.120.000204. Epub 2020 Oct 28.
5
Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme.计算机模拟鉴定的结核分枝杆菌烯酰-ACP（CoA）还原酶抑制剂的功能、热力学、结构和生物学研究。
Sci Rep. 2017 Apr 24;7:46696. doi: 10.1038/srep46696.
6
2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains.2-（喹啉-4-基氧基）乙酰胺对药物敏感和耐药结核分枝杆菌菌株均有活性。
ACS Med Chem Lett. 2016 Jan 11;7(3):235-9. doi: 10.1021/acsmedchemlett.5b00324. eCollection 2016 Mar 10.
7
First use of bedaquiline in a patient with XDR-TB in Singapore.新加坡首例使用贝达喹啉治疗广泛耐药结核病患者的情况。
BMJ Case Rep. 2015 Sep 23;2015:bcr2015210961. doi: 10.1136/bcr-2015-210961.
8
Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment.过度细胞溶解反应预示着明显成功治疗后的结核病复发。
J Infect Dis. 2016 Feb 1;213(3):485-95. doi: 10.1093/infdis/jiv447. Epub 2015 Sep 7.
9
Outcome Assessments in Clinical Trials of Cryptococcal Meningitis: Considerations on Use of Early Fungicidal Activity as a Potential Surrogate Endpoint for All-Cause Mortality.隐球菌性脑膜炎临床试验中的疗效评估：关于将早期杀菌活性用作全因死亡率潜在替代终点的考量
Curr Treat Options Infect Dis. 2014 Jul 29;6(3):326-336. doi: 10.1007/s40506-014-0026-0.
10
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?贝达喹啉用于治疗耐多药结核病：前景光明还是令人失望？
Ther Adv Chronic Dis. 2015 Jul;6(4):170-84. doi: 10.1177/2040622315582325.